Gap finder

Search review questions

Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.

Population

Intervention or exposure

Comparison

Outcome

Any field or review title

Field or topic

Source

Review versions

1,590 questions in 129 reviews · Gynaecological, Neuro-oncology and Orphan Cancer

current versions

No studies 281 · 17.7%Ungraded 74 · 4.7%Very low 410 · 25.8%Low 420 · 26.4%Moderate 280 · 17.6%High 125 · 7.9%

Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.

Question	Effect	Evidence	Status / GRADE
Outpatients vs inpatients ‐ children Treatment failure · Children with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane	RR 1.04 [0.55, 1.99]	4 studies · 366 participants	Moderate
Outpatients vs inpatients ‐ children Mortality · Children with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane	RR 0.63 [0.15, 2.7]	3 studies · 329 participants	Moderate
Outpatients vs inpatients ‐ children Duration of fever (days) · Children with cancer who develop a low‐risk febrile neutropaenic event Outpatient treatment for people with cancer who develop a low‐risk febrile neutropaenic event (2019) · Cochrane	no estimate extracted	3 studies · 305 participants	Low
Dietary intervention vs control Mortality · people living beyond cancer Dietary interventions for adult cancer survivors (2019) · Cochrane	HR 0.98 [0.77, 1.23]	1 study · 3107 participants	Low
Dietary intervention vs control Secondary cancers · people living beyond cancer Dietary interventions for adult cancer survivors (2019) · Cochrane	RR 0.99 [0.84, 1.15]	1 study · 3107 participants	Low
Dietary intervention vs control Fruit and vegetable intake assessed as servings · people living beyond cancer Dietary interventions for adult cancer survivors (2019) · Cochrane	no estimate extracted	5 studies · 834 participants	Moderate
Dietary intervention vs control Fibre intake assessed as g · people living beyond cancer Dietary interventions for adult cancer survivors (2019) · Cochrane	no estimate extracted	2 studies · 3127 participants	Very low
Dietary intervention vs control Diet Quality Index · people living beyond cancer Dietary interventions for adult cancer survivors (2019) · Cochrane	no estimate extracted	3 studies · 747 participants	Moderate
Dietary intervention vs control Body mass index · people living beyond cancer Dietary interventions for adult cancer survivors (2019) · Cochrane	no estimate extracted	4 studies · 777 participants	Moderate
Dietary intervention vs control Waist‐to‐hip circumference assessed as cm · people living beyond cancer Dietary interventions for adult cancer survivors (2019) · Cochrane	no estimate extracted	2 studies · 106 participants	Low
Robot‐assisted surgery vs conventional laparoscopic surgery Intraoperative and postoperative complications · women undergoing hysterectomy Robot‐assisted surgery in gynaecology (2019) · Cochrane	RR 0.92 [0.54, 1.59]	6 studies · 585 participants	Low
Robot‐assisted surgery vs conventional laparoscopic surgery Total operating time · gynaecology Robot‐assisted surgery in gynaecology (2019) · Cochrane	no estimate extracted	3 studies · 186 participants	Low
Robot‐assisted surgery vs conventional laparoscopic surgery Overall hospital stay · gynaecology Robot‐assisted surgery in gynaecology (2019) · Cochrane	no estimate extracted	2 studies · 108 participants	Very low
Robot‐assisted surgery vs conventional laparoscopic surgery Blood transfusions · gynaecology Robot‐assisted surgery in gynaecology (2019) · Cochrane	no estimate extracted	NR	No studies
Robot‐assisted surgery vs conventional laparoscopic surgery Intraoperative complications · women undergoing hysterectomy Robot‐assisted surgery in gynaecology (2019) · Cochrane	RR 1.05 [0.31, 3.56]	5 studies · 487 participants	Low
Robot‐assisted surgery vs conventional laparoscopic surgery Postoperative complications · women undergoing hysterectomy Robot‐assisted surgery in gynaecology (2019) · Cochrane	RR 0.82 [0.42, 1.59]	5 studies · 533 participants	Low
Robot‐assisted surgery vs conventional laparoscopic surgery Total operating time · women undergoing hysterectomy Robot‐assisted surgery in gynaecology (2019) · Cochrane	no estimate extracted	2 studies · 148 participants	Very low
Robot‐assisted surgery vs conventional laparoscopic surgery Overall hospital stay · women undergoing hysterectomy Robot‐assisted surgery in gynaecology (2019) · Cochrane	no estimate extracted	2 studies · 192 participants	Very low
Robot‐assisted surgery vs conventional laparoscopic surgery Blood transfusions · women undergoing hysterectomy Robot‐assisted surgery in gynaecology (2019) · Cochrane	RR 2.49 [0.75, 8.23]	4 studies · 346 participants	Low
Robot‐assisted surgery vs conventional laparoscopic surgery Intraoperative and postoperative complications · gynaecology Robot‐assisted surgery in gynaecology (2019) · Cochrane	RR 0.95 [0.21, 4.24]	3 studies · 186 participants	Very low
Robot‐assisted surgery vs conventional laparoscopic surgery Intraoperative complications · gynaecology Robot‐assisted surgery in gynaecology (2019) · Cochrane	RR 0.82 [0.09, 7.59]	2 studies · 108 participants	Very low
Robot‐assisted surgery vs conventional laparoscopic surgery Postoperative complications · gynaecology Robot‐assisted surgery in gynaecology (2019) · Cochrane	RR 3.54 [1.31, 9.56]	1 study · 68 participants	Low
mTOR inhibitors vs chemotherapy/hormone therapy Progression‐free survival: first‐line trials ( · women with advanced or recurrent endometrial cancer PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer (2019) · Cochrane	HR 1.43 [1.06, 1.93]	1 study · 231 participants	Low
mTOR inhibitors vs chemotherapy/hormone therapy Quality of life ‐ not reported · women with advanced or recurrent endometrial cancer PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer (2019) · Cochrane	no estimate extracted	NR	No studies
mTOR inhibitors vs chemotherapy/hormone therapy Progression‐free survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer (2019) · Cochrane	HR 0.53 [0.31, 0.91]	1 study · 95 participants	Moderate
mTOR inhibitors vs chemotherapy/hormone therapy Haematological toxicities ‐ Anaemia · women with advanced or recurrent endometrial cancer PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer (2019) · Cochrane	RR 1.42 [0.83, 2.44]	2 studies · 357 participants	Low
mTOR inhibitors vs chemotherapy/hormone therapy Skin toxicities ‐ Mucositis · women with advanced or recurrent endometrial cancer PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer (2019) · Cochrane	RR 10.42 [1.34, 80.74]	2 studies · 357 participants	Low
mTOR inhibitors vs chemotherapy/hormone therapy Respiratory toxicity ‐ Interstitial pneumonitis · women with advanced or recurrent endometrial cancer PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer (2019) · Cochrane	RR 7.36 [0.88, 61.52]	2 studies · 357 participants	Low
mTOR inhibitors vs chemotherapy/hormone therapy Overall survival: first‐line trials ( · women with advanced or recurrent endometrial cancer PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer (2019) · Cochrane	HR 1.32 [0.98, 1.78]	1 study · 231 participants	Low
mTOR inhibitors vs chemotherapy/hormone therapy Overall survival: second/third‐line trials ( · women with advanced or recurrent endometrial cancer PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer (2019) · Cochrane	HR 1.06 [0.7, 1.61]	1 study · 130 participants	Low
mTOR inhibitors vs chemotherapy/hormone therapy Objective response rate: first‐line trial · women with advanced or recurrent endometrial cancer PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer (2019) · Cochrane	RR 0.93 [0.75, 1.17]	1 study · 231 participants	Low
mTOR inhibitors vs chemotherapy/hormone therapy Objective response rate: second/third‐line trials · women with advanced or recurrent endometrial cancer PI3K/AKT/mTOR inhibitors for advanced or recurrent endometrial cancer (2019) · Cochrane	RR 0.22 [0.01, 4.4]	1 study · 61 participants	Low
Early discontinuation of antibiotic treatment vs treatment until neutropenia resolution Mortality · febrile neutropenia Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia… (2019) · Cochrane	RR 1.38 [0.73, 2.62]	8 studies · 603 participants	Low
Early discontinuation of antibiotic treatment vs treatment until neutropenia resolution Clinical failure · febrile neutropenia Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia… (2019) · Cochrane	RR 1.23 [0.85, 1.77]	7 studies · 645 participants	Very low
Early discontinuation of antibiotic treatment vs treatment until neutropenia resolution Any bacteraemia · febrile neutropenia Early discontinuation of antibiotics for febrile neutropenia versus continuation until neutropenia… (2019) · Cochrane	RR 1.56 [0.91, 2.66]	8 studies · 662 participants	Very low
Screening of psychosocial well‐being and care needs vs usual care HRQoL · People with cancer Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer (2019) · Cochrane	no estimate extracted	14 studies · 5752 participants	Very low
Screening of psychosocial well‐being and care needs vs usual care Distress · People with cancer Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer (2019) · Cochrane	no estimate extracted	13 studies · 5577 participants	Very low
Screening of psychosocial well‐being and care needs vs usual care Care needs · People with cancer Systematic screening and assessment of psychosocial well‐being and care needs of people with cancer (2019) · Cochrane	no estimate extracted	4 studies · 2331 participants	Very low
Intervention NR Caregiver psychological distress · caregiver well‐being Interventions to help support caregivers of people with a brain or spinal cord tumour (2019) · Cochrane	no estimate extracted	6 studies · 6 participants	Low
Intervention NR Caregiver burden · caregiver well‐being Interventions to help support caregivers of people with a brain or spinal cord tumour (2019) · Cochrane	no estimate extracted	2 studies · 2 participants	Low
Intervention NR Caregiver mastery · caregiver well‐being Interventions to help support caregivers of people with a brain or spinal cord tumour (2019) · Cochrane	no estimate extracted	2 studies · 2 participants	Very low
Intervention NR Quality of patient–caregiver relationship · caregiver well‐being Interventions to help support caregivers of people with a brain or spinal cord tumour (2019) · Cochrane	no estimate extracted	1 study · 1 participants	Very low
Intervention NR Caregiver quality of life · caregiver well‐being Interventions to help support caregivers of people with a brain or spinal cord tumour (2019) · Cochrane	no estimate extracted	6 studies · 6 participants	Very low
Intervention NR Caregiver physical functioning – not measured · caregiver well‐being Interventions to help support caregivers of people with a brain or spinal cord tumour (2019) · Cochrane	no estimate extracted	NR	No studies
Intervention NR Overall survival · women with stage Ia2 to IIa cervical cancer Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage… (2019) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Intervention NR Rate of ISC one month after operation · women with stage Ia2 to IIa cervical cancer Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage… (2019) · Cochrane	no estimate extracted	0 studies · 0 participants	Ungraded
Intervention NR Time to PVR ≤ 50 mL (days) · women with stage Ia2 to IIa cervical cancer Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage… (2019) · Cochrane	no estimate extracted	2 studies · 111 participants	Low
Intervention NR PVR one month after operation (mL) · women with stage Ia2 to IIa cervical cancer Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage… (2019) · Cochrane	no estimate extracted	1 study · 86 participants	Low
Intervention NR Perioperative complications (excluding bladder dysfunction) · women with stage Ia2 to IIa cervical cancer Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage… (2019) · Cochrane	RR 0.55 [0.24, 1.26]	3 studies · 180 participants	Low
Intervention NR Disease‐free survival (median · women with stage Ia2 to IIa cervical cancer Nerve‐sparing radical hysterectomy compared to standard radical hysterectomy for women with early stage… (2019) · Cochrane	HR 0.63 [0, 106.95]	1 study · 86 participants	Very low